Amisulpride in Huntington's disease;Der einsatz von amisulprid bei patienten mit morbus Huntington

Psychiatrische Praxis

Volumn 32, Issue 7, 2005, Pages 363-366

  Saft, Carsten ^a   Andrich, Jürgen ^a   Kraus, Peter H ^a   Przuntek, Horst ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE;

ADULT; ARTICLE; CASE REPORT; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HUNTINGTON CHOREA; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SIDE EFFECT;

AGED; ANTIPSYCHOTIC AGENTS; DELUSIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE, SECONDARY; PSYCHOTIC DISORDERS; SULPIRIDE; TREATMENT OUTCOME;

EID: 27644517860     PISSN: 03034259     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-815024     Document Type: Article

References (21)

1. Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi RE, Watkins PC, Ottina K, Wallace MR, Sakaguchi AY et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983; 306 (5940): 234-238
2. Weindl A, Conrad B. Chorea und choreatische Bewegungsstörungen. In: Conrad B, Ceballos-Baumann AO (Hrsg): Bewegungsstörungen in der Neurologie. Stuttgart, New York: Thieme, 1996: 155-180
3. Kanzig S, Eichorn M. Psychotic syndrome in chorea Huntington. Psychiatr Prax 2003; 30(5): 286-287
4. Schoenfield M, Myers RH. Increased rate of suicide among patients with Huntington's disease. J Neurol Neurosurg Psychiat 1984; 47: 1283
5. Berardelli A, Noth J, Thompson PD, Bollen EL, Curra A, Deuschl G, Dijk JG van, Topper R, Schwarz M, Roos RA. Pathophysiology of chorea and bradykinesia in Huntington's disease. Review. Mov Disord 1999; 14 (3): 398-403
6. Anderson KE, Marder KS. An overview of psychiatric symptoms in Huntington's disease. Review. Curr Psychiatry Rep 2001; 3(5): 379-388
7. Schoemaker H, Claustre Y, Page D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997; 280(1): 83-97
8. Delcker A, Schoon ML, Oczkowski B, Gaertner HJ. Amisulpride versus haloperidol in treatment of schizophrenic patients-results of a double-blind study. Pharmacopsychiatry 1990; 23(3): 125-301
9. Moller HJ, Boyer P, Fleurot O, Rein W. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. Psychopharmacology (Berl) 1997; 132 (4): 396-401
10. Wetzel H, Grunder G, Hillert A, Philipp M, Gattaz WF, Sauer H, Adler G, Schröder J, Rein W, Benkert O. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology (Berl) 1998; 137(3): 223-232
11. Peuskens J, Bech P, Moller HJ, Bale R, Fleurot O, Rein W. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res 1999; 88(2): 107-117
12. Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry 1999; 156(4): 610-616
13. Colonna L, Saleem P, Dondey-Nouvel L, Rein W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol 2000; 15(1): 13-22
14. Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002; 159(2): 180-190
15. Coulouvrat C, Dondey-Nouvel L Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 1999; 14(4): 209-218
16. Schotte A, Janssen PF, Gommeren W, Luyten WH, Compel P van, Lesage AS, Loore K de, Leysen JE. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996; 124(1-2): 57-73
17. Rein W, Coulouvrat C, Dondey-Nouvel L. Safety profile of amisulpride in short- and long-term use. Acta Psychiatr Scand Suppl 2000; 400: 23-27
18. Briken P, Nika E, Krausz M, Naber D. Atypical neuroleptics in the treatment of aggression and hostility in schizophrenic patients. Fortschr Neurol Psychiatr 2002; 70(3): 139-144
19. Tarsy D, Baldessarini RJ, Tarazi F. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002; 16(1): 23-45
20. Green B. Focus on amisulpride. Curr Med Res Opin 2002; 18(3): 113-117
21. Saleem P, Olie JP, Loo H. Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride. Int Clin Psychopharmacol 2002; 17(1): 1-8